Zimbabwe has authorized a twice-yearly HIV prevention injection that provides six months of protection against the virus, with regulators completing their safety review in just 23 days. Medicines Control Authority director Richard Rukwata announced approval of Lenacapavir for adults and adolescents weighing at least 35 kilograms, positioning the southern African nation among 10 countries worldwide selected to distribute the pharmaceutical developed by Gilead.
The long-acting treatment aims to reach two million people across high-burden regions through funding from the Global Fund and the US President's Emergency Plan for Aids Relief. Health advocates emphasized the need for affordable pricing and domestic financing mechanisms to ensure sustainable access beyond external donor support.
The long-acting treatment aims to reach two million people across high-burden regions through funding from the Global Fund and the US President's Emergency Plan for Aids Relief. Health advocates emphasized the need for affordable pricing and domestic financing mechanisms to ensure sustainable access beyond external donor support.
